The discovery of dopamine deficiency as a cause of the disability of Parkinson’s disease has led to an era of successful dopaminergic therapy. Professor Jeremy Playfer provides an overview of the evolution of dopamine agonists and their use, starting from the 1960s through to what innovative new therapy options are available today and which may best suit the older patient in the early and late stages of the disease.